Makary’s FDA Reforms Continue to Advance Amid Leadership Turmoil

Makary’s FDA reforms continue to advance in 2026 even as political and personnel turmoil swirl around the agency

several of Makary’s signature initiatives—such as the National Priority Vouchers, streamlined biologic and gene‑therapy pathways, and sweeping transparency measures—have remained on track despite leadership uncertainty

the FDA has also continued to implement controversial food reforms, including removal of synthetic petroleum‑based dyes, tougher scrutiny of chemicals such as BHT and BHA, and a major overhaul of the ‘generally recognized as safe’ (GRAS) loophole

advisory‑committee and conflict‑of‑interest changes limiting industry employees on panels have survived multiple leadership and political pressures, amid ongoing criticism from both industry and some public‑health advocates

modernization of IT and data systems, including consolidation of adverse‑event databases and real‑time reporting portals, has proceeded under Makary’s ‘radical transparency’ agenda even as the commissioner’s own status has been debated in Congress and the press

the agency has also maintained its push to shorten drug approval timelines via AI‑assisted reviews, continuous‑trial pilots, and the one‑trial policy for select applications, despite concern that the pace could compromise scientific rigor

commentators note that Makary’s mix of deregulatory and pro‑safety moves has kept the FDA in the spotlight, but many reforms appear to have taken root enough to outlast near‑term leadership changes